"Insulin Glargine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.
| Descriptor ID |
D000069036
|
| MeSH Number(s) |
D06.472.699.587.200.300.100 D12.644.548.586.200.300.100
|
| Concept/Terms |
Insulin Glargine- Insulin Glargine
- Glargine, Insulin
- A21-Gly-B31-Arg-B32-Arg-insulin
- A21 Gly B31 Arg B32 Arg insulin
- Insulin, Glycyl(A21)-Arginyl(B31,B32)
- Glargine
- Insulin, Gly(A21)-Arg(B31,B32)
Lantus- Lantus
- Lantus Solostar
- Solostar, Lantus
HOE 901- HOE 901
- 901, HOE
- HOE-901
- HOE901
|
Below are MeSH descriptors whose meaning is more general than "Insulin Glargine".
Below are MeSH descriptors whose meaning is more specific than "Insulin Glargine".
This graph shows the total number of publications written about "Insulin Glargine" by people in this website by year, and whether "Insulin Glargine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 1 | 2 |
| 2017 | 11 | 2 | 13 |
| 2018 | 9 | 2 | 11 |
| 2019 | 4 | 2 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Insulin Glargine" by people in Profiles.
-
Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine. Ital J Pediatr. 2021 Jun 02; 47(1):121.
-
Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study. Clin Drug Investig. 2019 Aug; 39(8):745-756.
-
IDegLira: combining efficacy, durability, and convenience? Lancet Diabetes Endocrinol. 2019 08; 7(8):584-585.
-
[Basal insulin degludec (Tresiba®)]. Rev Med Liege. 2019 Apr; 74(4):226-232.
-
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology. 2019 06; 69(6):2414-2426.
-
Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes. Drugs. 2019 Feb; 79(2):173-186.
-
[Basal insulin glargine-lixisenatide fixed ratio combination (Suliqua®)]. Rev Med Liege. 2019 Feb; 74(2):111-116.
-
Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial. Diabetes Obes Metab. 2019 04; 21(4):837-843.
-
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. Diabetes Obes Metab. 2019 04; 21(4):781-790.
-
Expert Group Recommendations on Detection and Management of Hypoglycemia in Routine Clinical Practice in Insulin Treated Patients with Diabetes. J Assoc Physicians India. 2018 Dec; 66(12):90-97.